SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SemiBull who wrote (876)2/3/2002 4:34:47 PM
From: SemiBull  Read Replies (1) of 1139
 
ICOS Scheduled at Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference

BOTHELL, Wash.--(BW HealthWire)--Feb. 1, 2002--ICOS Corporation (Nasdaq:ICOS - news) announced today that Paul Clark, ICOS Chairman and CEO, will speak at the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference on February 6, 2002 at 10:45 a.m. EST. The conference is being held at the Grand Hyatt Hotel in New York, New York.

A webcast of the presentation will be available in real-time and a replay (for 48 hours). The webcast can be accessed on the ICOS website, www.icos.com, Investor section. Additional information on ICOS, including press releases, is also available on the website.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing the Company's opportunities for marketing breakthrough products.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company's latest Annual Report on Form 10-K and its other public filings filed with the SEC.

--------------------------------------------------------------------------------
Contact:

ICOS Corporation
Lacy Fitzpatrick
(425) 415-2207
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext